GE builds diagnostics business with $587M Clarient buyout

GE on Friday announced plans to buy Clarient--a molecular diagnostics company with a strong focus on cancer markers--for $587 million. GE Healthcare is planning to build itself into a billion-dollar business marketing diagnostic solutions for healthcare providers. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.